Based on the AIM ImmunoTech Inc stock forecast from 0 analysts, the average analyst target price for AIM ImmunoTech Inc is not available over the next 12 months. AIM ImmunoTech Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AIM ImmunoTech Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, AIM ImmunoTech Inc’s stock price was USD 0.15. AIM ImmunoTech Inc’s stock price has changed by -16.49% over the past week, -30.05% over the past month and -62.22% over the last year.
No recent analyst target price found for AIM ImmunoTech Inc
No recent average analyst rating found for AIM ImmunoTech Inc
Company Overview AIM ImmunoTech Inc
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Read Less
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecu...Read More
Frequently Asked Questions About AIM ImmunoTech Inc (AIM) Stock
Stock Target Advisor's fundamental analysis for AIM ImmunoTech Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on AIM's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AIM's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AIM's stock to indicate if its overvalued.
The last closing price of AIM's stock was USD 0.15.
The most recent market capitalization for AIM is USD 0.01B.
Unfortunately we do not have enough analyst data on AIM's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AIM ImmunoTech Inc's stock.
As per our most recent records AIM ImmunoTech Inc has 26 Employees.
AIM ImmunoTech Inc's registered address is 2117 SW Highway 484, Ocala, FL, United States, 34473.
You can get more information about it from AIM ImmunoTech Inc's website at https://aimimmuno.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About AIM ImmunoTech Inc (AIM) Stock
Stock Target Advisor's fundamental analysis for AIM ImmunoTech Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on AIM's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AIM's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AIM's stock to indicate if its overvalued.
The last closing price of AIM's stock was USD 0.15.
The most recent market capitalization for AIM is USD 0.01B.
Unfortunately we do not have enough analyst data on AIM's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AIM ImmunoTech Inc's stock.
As per our most recent records AIM ImmunoTech Inc has 26 Employees.
AIM ImmunoTech Inc's registered address is 2117 SW Highway 484, Ocala, FL, United States, 34473.
You can get more information about it from AIM ImmunoTech Inc's website at https://aimimmuno.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AIM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
